Skip to main content

Table 1 Activity of PD-1-pathway-targeted agents in patients with advanced Merkel cell carcinoma

From: Immunotherapy for Merkel cell carcinoma: a turning point in patient care

Drug name

Drug class

N

Number of prior systemic therapies

ORR (%)

Reference

Avelumab

Anti-PD-L1

88

1–4

33

[40]

29

0

65

[53]

Nivolumab

Anti-PD-1

15

0

73*

[44]

10

1–2

50*

Pembrolizumab

Anti-PD-1

26

0

56

[35]

  1. *RECIST v1.1, investigator assessed